贫血患者接受颈动脉血运重建术后的结局比较
基于血管质量倡议数据库2016至2023年的回顾性分析,比较贫血患者接受颈动脉内膜剥脱术(CEA)、经股动脉颈动脉支架置入术(TFCAS)和经颈动脉血运重建术(TCAR)的术后结局。共纳入40,383例CEA、9,159例TFCAS和18,555例TCAR。与CEA和TCAR相比,TFCAS与更高的30天死亡率和院内主要不良心脏事件(MACE)风险相关;TCAR与CEA相比30天死亡率风险更低。作者认为TCAR可能是贫血患者颈动脉血运重建的最佳微创方式。
要点
- 贫血患者中,TFCAS较CEA的30天死亡率风险升高(aOR 2),院内MACE风险也升高(aOR 1.7)。
- TCAR较TFCAS的30天死亡率(aOR 0.45)和院内MACE(aOR 0.58)风险均更低。
- TCAR较CEA的30天死亡率风险降低20%(aOR 0.80),院内MACE风险相似(aOR 0.86,P = .07)。
核心结论
- 在贫血患者中,TFCAS与CEA和TCAR相比,30天死亡率和院内MACE风险更高;TCAR与CEA相比30天死亡率风险更低。
- 作者认为这些发现提示TCAR是贫血患者颈动脉血运重建的最佳微创方式。
研究设计与样本
- 回顾性分析血管质量倡议数据库中2016至2023年接受CEA、TFCAS和TCAR的贫血患者。
- 贫血定义为男性术前血红蛋白<13 g/dL、女性<12 g/dL。
- 共纳入40,383例CEA(59.3%)、9,159例TFCAS(13.5%)和18,555例TCAR(27.3%)。
- 主要结局为30天死亡率和院内主要不良心脏事件(MACE),采用逻辑回归进行多变量分析。
主要发现
- TCAR患者较CEA和TFCAS患者年龄更大且合并症更多。
- TCAR较TFCAS:30天死亡率aOR 0.45(95%CI 0.37-0.59,P < .001),院内MACE aOR 0.58(95%CI 0.46-0.75,P < .001)。
- TCAR较CEA:30天死亡率aOR 0.80(95%CI 0.65-0.98,P = .03),院内MACE aOR 0.86(95%CI 0.77-1.01,P = .07)。
- TFCAS较CEA:30天死亡率aOR 2(95%CI 1.5-2.68,P < .001),院内MACE aOR 1.7(95%CI 1.4-2,P < .001)。
临床怎么用
- 作者认为TCAR可能是贫血患者颈动脉血运重建的最佳微创方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative anemia is associated with worse postoperative morbidity and mortality after major vascular procedures. Limited research has examined the optimal method of carotid revascularization in patients with anemia. Therefore, we aim to compare the postoperative outcomes after carotid endarterectomy (CEA), transfemoral carotid artery stenting (TFCAS), and transcarotid artery revascularization (TCAR) among patients with anemia. STUDY DESIGN: This is a retrospective review of patients with anemia undergoing CEA, TFCAS, and TCAR in the Vascular Quality Initiative database between 2016 and 2023. We defined anemia as a preoperative hemoglobin level of <13 g/dL in men and <12 g/dL in women. The primary outcomes were 30-day mortality and in-hospital major adverse cardiac events (MACE). Logistic regression models were used for multivariate analyses. RESULTS: Our study included 40,383 CEA (59.3%), 9159 TFCAS (13.5%), and 18,555 TCAR (27.3%) cases in patients with anemia. TCAR patients were older and had more medical comorbidities than CEA and TFCAS patients. TCAR was associated with a decreased 30-day mortality (adjusted odds ratio [aOR], 0.45; 95% confidence interval [CI], 0.37-0.59; P < .001), in-hospital MACE (aOR, 0.58; 95% CI, 0.46-0.75; P < .001) compared with TFCAS. Additionally, TCAR was associated with a 20% decrease in the risk of 30-day mortality (aOR, 0.80; 95% CI, 0.65-0.98; P = .03) and a similar risk of in-hospital MACE (aOR, 0.86; 95% CI, 0.77-1.01; P = .07) compared with CEA. Furthermore, TFCAS was associated with an increased risk of 30-day mortality (aOR, 2; 95% CI, 1.5-2.68; P < .001) and in-hospital MACE (aOR, 1.7; 95% CI, 1.4-2; P < .001) compared with CEA. CONCLUSIONS: In this multi-institutional national retrospective analysis of a prospectively collected database, TFCAS was associated with a high risk of 30-day mortality and in-hospital MACE compared with CEA and TCAR in patients with anemia. TCAR was associated with a lower risk of 30-day mortality compared with CEA. These findings suggest TCAR as the optimal minimally invasive procedure for carotid revascularization in patients with anemia.
引用
- Abdelkarim A, Straus SL, Moghaddam M, et al. Postoperative outcomes in patients with anemia undergoing carotid revascularization. J Vasc Surg. 2024. PMID: 39179005. doi:10.1016/j.jvs.2024.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。